CDK2 and neoplasm: We have previously demonstrated in preclinical models that CDK4/6 inhibitors, when combined with MDM2 inhibition, can effectively inhibit melanoma tumor growth, and that resistance to CDK4/6 inhibition can be overcome through the targeted deletion of CDK2 (17).